The US federal government has named the next 15 medicines that will be subject to Medicare pricing negotiation and reductions due to come into effect at the start of 2028. The list has been announced ...

Ozempic. Wegovy. Mounjaro. Trulicity. Competing brands. Differing active ingredients and formats. But one huge opportunity. GLP-1 medications occupy unprecedented territory: prescription products with ...

This article is the latest in the Health Affairs Forefront featured topic, “Health Policy at a Crossroads,” produced with the support of the Commonwealth Fund and the Robert Wood Johnson Foundation.

After Novo Nordisk projected yesterday that its revenue could decline by as much as 13% in 2026, its share price has plummeted by 20%. Because the Danish company attributed much of the shortfall to ...

(The Hill) – The Trump administration on Tuesday announced the 15 drugs selected to participate in the newest round of the Medicare Drug Price Negotiation Program, including the high-cost medications ...